



**Keystone 65 Rx HMO  
Personal Choice 65<sup>SM</sup> Rx PPO  
Select Option<sup>®</sup> Rx PDP**

**2025 Utilization Management Criteria: Step Therapy**

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION  
ABOUT SOME OF THE DRUGS WE COVER IN THIS PLAN**

This document was updated on **10/01/2024**. For more recent information or other questions, please contact our Member Help Team: Keystone 65 Rx at **1-844-352-1699**, Personal Choice 65 Rx at **1-888-879-4293**, Select Option Rx at **1-888-678-7009** or, for TTY/TDD users, **711**, seven days a week from 8 a.m. to 8 p.m. Please note that on weekends and holidays from April 1 through September 30, your call may be sent to voicemail. Or, visit [www.ibxmedicare.com](http://www.ibxmedicare.com) to use our *Formulary (List of Covered Drugs)* search tool or view a downloadable document.

When this document refers to “we,” “us,” or “our,” it means Independence Blue Cross. When it refers to “plan” or “our plan,” it means Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2026, and from time to time during the year.

Independence Blue Cross offers PPO, HMO-POS, and HMO Medicare Advantage plans with a Medicare contract. Enrollment in Independence Blue Cross PPO, HMO-POS, and HMO Medicare Advantage plans depends on contract renewal.

Independence Blue Cross offers products through its subsidiaries Independence Assurance Company, Independence Hospital Indemnity Plan, Keystone Health Plan East, and QCC Insurance Company — independent licensees of the Blue Cross and Blue Shield Association.

## There may be restrictions to your drug coverage

Some covered drugs may have additional requirements or limits on coverage. We call this “utilization management.” These requirements and limits may include:

- **Prior Authorization (PA):** Our plan requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from our plan before you fill your prescriptions. If you don’t get approval, our plan may not cover the drug. Drugs that require prior authorization are listed in *2025 Utilization Management Criteria: Prior Authorization*.
- **Step Therapy (ST):** In some cases, our plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. Drugs that require step therapy are listed in this document.
- **Quantity Limits (QL):** For certain drugs, our plan limits the amount of the drug that our plan will cover. Drugs that have quantity limits are listed in the *Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx Formulary (List of Covered Drugs)*.

You can find out if your drug has any additional requirements or limits by looking in your plan *Formulary (List of Covered Drugs)*. You can also get more information about the restrictions applied to specific covered drugs by visiting [www.ibxmedicare.com](http://www.ibxmedicare.com).

You can ask our plan to make an exception to these restrictions or limits, or for a list of other similar drugs that may treat your health condition. Your *Formulary (List of Covered Drugs)* and *Evidence of Coverage* will have more information about the exception request process.

## How to use this document

This document, along with *2025 Utilization Management Criteria: Prior Authorization*, is intended to be used with your *Formulary (List of Covered Drugs)*. If your prescription drug has the note “ST” in the “Requirements” column of the *Keystone 65 Rx, Personal Choice 65 Rx, and Select Option Rx Formulary (List of Covered Drugs)*, you can find more information on the restriction(s) in this document.

Locate your drug in the index on page 23. The restriction information includes step therapy criteria.

Be sure to read all the information listed for your affected drug. If you have any questions or need assistance with the information contained in this document, please call our Member Help Team: Keystone 65 Rx at **1-844-352-1699**, Personal Choice 65 Rx at **1-888-879-4293**, or Select Option Rx at **1-888-678-7009** or, for TTY/TDD users, **711**.

# ANTICONVULSANTS 2025 - Pending CMS Review

---

## Products Affected

- VIGAFYDE SOLUTION 100 MG/ML ORAL

## Details

<b>Criteria</b>	Trial of two generic formulary anticonvulsants. Applies to new starts.
-----------------	--

---

# ANTIDEPRESSANTS [SNRIS] 2025

---

## Products Affected

- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL
- FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL

## Details

<b>Criteria</b>	Trial of two generic formulary serotonin-norepinephrine reuptake Inhibitor (SNRI). Applies to new starts.
-----------------	---

# BRAND ANTIPSYCHOTICS 2025

---

## Products Affected

- FANAPT TABLET 1 MG ORAL
- FANAPT TABLET 10 MG ORAL
- FANAPT TABLET 12 MG ORAL
- FANAPT TABLET 2 MG ORAL
- FANAPT TABLET 4 MG ORAL
- FANAPT TABLET 6 MG ORAL
- FANAPT TABLET 8 MG ORAL
- REXULTI TABLET 0.25 MG ORAL
- REXULTI TABLET 0.5 MG ORAL
- REXULTI TABLET 1 MG ORAL
- REXULTI TABLET 2 MG ORAL
- REXULTI TABLET 3 MG ORAL
- REXULTI TABLET 4 MG ORAL
- SECUADO PATCH 24 HOUR 3.8 MG/24HR  
TRANSDERMAL
- SECUADO PATCH 24 HOUR 5.7 MG/24HR  
TRANSDERMAL
- SECUADO PATCH 24 HOUR 7.6 MG/24HR  
TRANSDERMAL
- VRAYLAR CAPSULE 1.5 MG ORAL
- VRAYLAR CAPSULE 3 MG ORAL
- VRAYLAR CAPSULE 4.5 MG ORAL
- VRAYLAR CAPSULE 6 MG ORAL

## Details

<b>Criteria</b>	Trial of two generic formulary antipsychotic products. Applies to new starts.
-----------------	---

# BRAND BUPROPION PRODUCTS 2025

---

## Products Affected

- WELLBUTRIN XL TABLET EXTENDED RELEASE 24 HOUR 150 MG ORAL
- WELLBUTRIN XL TABLET EXTENDED RELEASE 24 HOUR 300 MG ORAL

## Details

<b>Criteria</b>	Trial of one generic formulary bupropion product. Applies to new starts.
-----------------	--

# CITALOPRAM CAPSULE 2025

---

## Products Affected

- *citalopram hydrobromide capsule 30 mg oral*

## Details

<b>Criteria</b>	Trial of both generic formulary citalopram oral solution and tablet. Applies to new starts.
-----------------	---

---

# DRIZALMA 2025 - Pending CMS Review

---

## Products Affected

- DRIZALMA SPRINKLE CAPSULE DELAYED  
RELEASE SPRINKLE 20 MG ORAL
- DRIZALMA SPRINKLE CAPSULE DELAYED  
RELEASE SPRINKLE 30 MG ORAL
- DRIZALMA SPRINKLE CAPSULE DELAYED  
RELEASE SPRINKLE 40 MG ORAL
- DRIZALMA SPRINKLE CAPSULE DELAYED  
RELEASE SPRINKLE 60 MG ORAL

## Details

<b>Criteria</b>	Trial of generic formulary duloxetine. Applies to new starts.
-----------------	---

---



# DYMISTA 2025

---

## Products Affected

- *azelastine-fluticasone suspension 137-50 mcg/act nasal*

## Details

<b>Criteria</b>	Trial of both generic formulary fluticasone nasal spray and azelastine nasal spray. Always applies.
-----------------	---

---

# EPRONTIA 2025

---

## Products Affected

- EPRONTIA SOLUTION 25 MG/ML ORAL

## Details

<b>Criteria</b>	Trial of generic formulary topiramate. Applies to new starts.
-----------------	---

# GOUT AGENTS 2025

---

## Products Affected

- *febuxostat tablet 40 mg oral*
- *febuxostat tablet 80 mg oral*

## Details

<b>Criteria</b>	Trial of generic formulary allopurinol 100mg or 300mg. Always applies.
-----------------	--

# INSULIN GLARGINE 2025

---

## Products Affected

- BASAGLAR KWIKPEN SOLUTION PEN-INJECTOR 100 UNIT/ML SUBCUTANEOUS
- BASAGLAR TEMPO PEN SOLUTION PEN-INJECTOR 100 UNIT/ML SUBCUTANEOUS

## Details

<b>Criteria</b>	Trial of two of the following: Lantus, Toujeo, Tresiba. Always applies.
-----------------	---

# MULTIPLE SCLEROSIS AGENTS 2025

---

## Products Affected

- AUBAGIO TABLET 14 MG ORAL
- AUBAGIO TABLET 7 MG ORAL
- COPAXONE SOLUTION PREFILLED SYRINGE 20 MG/ML SUBCUTANEOUS
- COPAXONE SOLUTION PREFILLED SYRINGE 40 MG/ML SUBCUTANEOUS
- KESIMPTA SOLUTION AUTO-INJECTOR 20 MG/0.4ML SUBCUTANEOUS
- MAVENCLAD (8 TABS) TABLET THERAPY PACK 10 MG ORAL
- MAVENCLAD (9 TABS) TABLET THERAPY PACK 10 MG ORAL
- REBIF REBIDOSE SOLUTION AUTO-INJECTOR 22 MCG/0.5ML SUBCUTANEOUS
- REBIF REBIDOSE SOLUTION AUTO-INJECTOR 44 MCG/0.5ML SUBCUTANEOUS
- REBIF REBIDOSE TITRATION PACK SOLUTION AUTO-INJECTOR 6X8.8 & 6X22 MCG SUBCUTANEOUS
- REBIF SOLUTION PREFILLED SYRINGE 22 MCG/0.5ML SUBCUTANEOUS
- REBIF SOLUTION PREFILLED SYRINGE 44 MCG/0.5ML SUBCUTANEOUS
- REBIF TITRATION PACK SOLUTION PREFILLED SYRINGE 6X8.8 & 6X22 MCG SUBCUTANEOUS
- VUMERITY CAPSULE DELAYED RELEASE 231 MG ORAL

## Details

<b>Criteria</b>	Trial of two of the following formulary products: (1) Avonex (interferon beta-1a), (2) Betaseron (interferon beta-1b), (3) Glatopa (glatiramer acetate), (4) Tecfidera (Dimethyl Fumarate), (5) Gilenya (fingolimod), (6) Teriflunomide. Applies to new starts.
-----------------	---

# OIC AGENTS 2025

---

## Products Affected

- RELISTOR SOLUTION 12 MG/0.6ML SUBCUTANEOUS
- RELISTOR SOLUTION 8 MG/0.4ML
- RELISTOR TABLET 150 MG ORAL

## Details

<b>Criteria</b>	Trial of lubiprostone or lactulose. Always Applies.
-----------------	---

---

# PEG-FILGRASTIM 2025

---

## Products Affected

- FULPHILA SOLUTION PREFILLED SYRINGE 6 MG/0.6ML SUBCUTANEOUS
- UDENYCA SOLUTION AUTO-INJECTOR 6 MG/0.6ML SUBCUTANEOUS
- UDENYCA SOLUTION PREFILLED SYRINGE 6 MG/0.6ML SUBCUTANEOUS
- ZIEXTENZO SOLUTION PREFILLED SYRINGE 6 MG/0.6ML SUBCUTANEOUS

## Details

<b>Criteria</b>	Trial of Neulasta. Always applies
-----------------	-----------------------------------

---

# PROTON PUMP INHIBITORS (PPIs) 2025

---

## Products Affected

- *rabeprazole sodium tablet delayed release 20 mg oral*

## Details

Criteria	
	Trial of two generic formulary proton pump inhibitors. Always applies.

---



# SANCUSO 2025 - Pending CMS Review

---

## Products Affected

- SANCUSO PATCH 3.1 MG/24HR TRANSDERMAL

## Details

<b>Criteria</b>	Trial of (a) ondansetron or granisetron and (b) aprepitant. Always applies.
-----------------	---

# SAVELLA 2025

---

## Products Affected

- SAVELLA TABLET 100 MG ORAL
- SAVELLA TABLET 12.5 MG ORAL
- SAVELLA TABLET 25 MG ORAL
- SAVELLA TABLET 50 MG ORAL
- SAVELLA TITRATION PACK 12.5 & 25 & 50 MG ORAL

## Details

<b>Criteria</b>	Trial of generic formulary duloxetine. Applies to new starts.
-----------------	---

---

# SERTRALINE CAPSULE 2025

---

## Products Affected

- *sertraline hcl capsule 150 mg oral*
- *sertraline hcl capsule 200 mg oral*

## Details

<b>Criteria</b>	Trial of both generic formulary sertraline oral concentrate and tablet. Applies to new starts.
-----------------	--

---

# TRULANCE 2025

---

## Products Affected

- TRULANCE TABLET 3 MG ORAL

## Details

<b>Criteria</b>	Trial of both of the following: (1) lactulose and (2) Linzess or lubiprostone. Always applies.
-----------------	---

---

# XCOPRI 2025

---

## Products Affected

- XCOPRI (250 MG DAILY DOSE) TABLET THERAPY PACK 100 & 150 MG ORAL
- XCOPRI (350 MG DAILY DOSE) TABLET THERAPY PACK 150 & 200 MG ORAL
- XCOPRI TABLET 100 MG ORAL
- XCOPRI TABLET 150 MG ORAL
- XCOPRI TABLET 200 MG ORAL
- XCOPRI TABLET 25 MG ORAL
- XCOPRI TABLET 50 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 150 MG & 14 X 200 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 50 MG & 14 X 100 MG ORAL

## Details

Details	
<b>Criteria</b>	Trial of two generic formulary anticonvulsants. Applies to new starts.

# ZONISADE 2025

---

## Products Affected

- ZONISADE SUSPENSION 100 MG/5ML ORAL

## Details

<b>Criteria</b>	Trial of generic zonisamide capsule. Applies to new starts.
-----------------	---

---

## Index

AUBAGIO TABLET 14 MG ORAL.....	13	MAVENCLAD (8 TABS) TABLET THERAPY	
AUBAGIO TABLET 7 MG ORAL.....	13	PACK 10 MG ORAL.....	13
<i>azelastine-fluticasone suspension 137-50</i>		MAVENCLAD (9 TABS) TABLET THERAPY	
<i>mcg/act nasal.....</i>	9	PACK 10 MG ORAL.....	13
BASAGLAR KWIKPEN SOLUTION PEN-		<i>rabeprazole sodium tablet delayed release 20</i>	
INJECTOR 100 UNIT/ML SUBCUTANEOUS.....	12	<i>mg oral.....</i>	16
BASAGLAR TEMPO PEN SOLUTION PEN-		REBIF REBIDOSE SOLUTION AUTO-INJECTOR	
INJECTOR 100 UNIT/ML SUBCUTANEOUS.....	12	22 MCG/0.5ML SUBCUTANEOUS.....	13
<i>citalopram hydrobromide capsule 30 mg oral.....</i>	7	REBIF REBIDOSE SOLUTION AUTO-INJECTOR	
COPAXONE SOLUTION PREFILLED SYRINGE		44 MCG/0.5ML SUBCUTANEOUS.....	13
20 MG/ML SUBCUTANEOUS.....	13	REBIF REBIDOSE TITRATION PACK SOLUTION	
COPAXONE SOLUTION PREFILLED SYRINGE		AUTO-INJECTOR 6X8.8 & 6X22 MCG	
40 MG/ML SUBCUTANEOUS.....	13	SUBCUTANEOUS.....	13
DRIZALMA SPRINKLE CAPSULE DELAYED		REBIF SOLUTION PREFILLED SYRINGE 22	
RELEASE SPRINKLE 20 MG ORAL.....	8	MCG/0.5ML SUBCUTANEOUS.....	13
DRIZALMA SPRINKLE CAPSULE DELAYED		REBIF SOLUTION PREFILLED SYRINGE 44	
RELEASE SPRINKLE 30 MG ORAL.....	8	MCG/0.5ML SUBCUTANEOUS.....	13
DRIZALMA SPRINKLE CAPSULE DELAYED		REBIF TITRATION PACK SOLUTION PREFILLED	
RELEASE SPRINKLE 40 MG ORAL.....	8	SYRINGE 6X8.8 & 6X22 MCG	
DRIZALMA SPRINKLE CAPSULE DELAYED		SUBCUTANEOUS.....	13
RELEASE SPRINKLE 60 MG ORAL.....	8	RELISTOR SOLUTION 12 MG/0.6ML	
EPRONTIA SOLUTION 25 MG/ML ORAL.....	10	SUBCUTANEOUS.....	14
FANAPT TABLET 1 MG ORAL.....	5	RELISTOR SOLUTION 8 MG/0.4ML	
FANAPT TABLET 10 MG ORAL.....	5	SUBCUTANEOUS.....	14
FANAPT TABLET 12 MG ORAL.....	5	RELISTOR TABLET 150 MG ORAL.....	14
FANAPT TABLET 2 MG ORAL.....	5	REXULTI TABLET 0.25 MG ORAL.....	5
FANAPT TABLET 4 MG ORAL.....	5	REXULTI TABLET 0.5 MG ORAL.....	5
FANAPT TABLET 6 MG ORAL.....	5	REXULTI TABLET 1 MG ORAL.....	5
FANAPT TABLET 8 MG ORAL.....	5	REXULTI TABLET 2 MG ORAL.....	5
<i>febuxostat tablet 40 mg oral.....</i>	11	REXULTI TABLET 3 MG ORAL.....	5
<i>febuxostat tablet 80 mg oral.....</i>	11	REXULTI TABLET 4 MG ORAL.....	5
FETZIMA CAPSULE EXTENDED RELEASE 24		SANCUSO PATCH 3.1 MG/24HR	
HOUR 120 MG ORAL.....	4	TRANSDERMAL.....	17
FETZIMA CAPSULE EXTENDED RELEASE 24		SAVELLA TABLET 100 MG ORAL.....	18
HOUR 20 MG ORAL.....	4	SAVELLA TABLET 12.5 MG ORAL.....	18
FETZIMA CAPSULE EXTENDED RELEASE 24		SAVELLA TABLET 25 MG ORAL.....	18
HOUR 40 MG ORAL.....	4	SAVELLA TABLET 50 MG ORAL.....	18
FETZIMA CAPSULE EXTENDED RELEASE 24		SAVELLA TITRATION PACK 12.5 & 25 & 50	
HOUR 80 MG ORAL.....	4	MG ORAL.....	18
FETZIMA TITRATION CAPSULE ER 24 HOUR		SECUADO PATCH 24 HOUR 3.8 MG/24HR	
THERAPY PACK 20 & 40 MG ORAL.....	4	TRANSDERMAL.....	5
FULPHILA SOLUTION PREFILLED SYRINGE 6		SECUADO PATCH 24 HOUR 5.7 MG/24HR	
MG/0.6ML SUBCUTANEOUS.....	15	TRANSDERMAL.....	5
KESIMPTA SOLUTION AUTO-INJECTOR 20		SECUADO PATCH 24 HOUR 7.6 MG/24HR	
MG/0.4ML SUBCUTANEOUS.....	13	TRANSDERMAL.....	5
		<i>sertraline hcl capsule 150 mg oral.....</i>	19

<i>sertraline hcl capsule 200 mg oral</i> .....	19
TRULANCE TABLET 3 MG ORAL.....	20
UDENYCA SOLUTION AUTO-INJECTOR 6 MG/0.6ML SUBCUTANEOUS.....	15
UDENYCA SOLUTION PREFILLED SYRINGE 6 MG/0.6ML SUBCUTANEOUS.....	15
VIGAFYDE SOLUTION 100 MG/ML ORAL.....	3
VRAYLAR CAPSULE 1.5 MG ORAL.....	5
VRAYLAR CAPSULE 3 MG ORAL.....	5
VRAYLAR CAPSULE 4.5 MG ORAL.....	5
VRAYLAR CAPSULE 6 MG ORAL.....	5
VUMERITY CAPSULE DELAYED RELEASE 231 MG ORAL.....	13
WELLBUTRIN XL TABLET EXTENDED RELEASE 24 HOUR 150 MG ORAL.....	6
WELLBUTRIN XL TABLET EXTENDED RELEASE 24 HOUR 300 MG ORAL.....	6
XCOPRI (250 MG DAILY DOSE) TABLET THERAPY PACK 100 & 150 MG ORAL.....	21
XCOPRI (350 MG DAILY DOSE) TABLET THERAPY PACK 150 & 200 MG ORAL.....	21
XCOPRI TABLET 100 MG ORAL.....	21
XCOPRI TABLET 150 MG ORAL.....	21
XCOPRI TABLET 200 MG ORAL.....	21
XCOPRI TABLET 25 MG ORAL.....	21
XCOPRI TABLET 50 MG ORAL.....	21
XCOPRI TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG ORAL.....	21
XCOPRI TABLET THERAPY PACK 14 X 150 MG & 14 X200 MG ORAL.....	21
XCOPRI TABLET THERAPY PACK 14 X 50 MG & 14 X100 MG ORAL.....	21
ZIEXTENZO SOLUTION PREFILLED SYRINGE 6 MG/0.6ML SUBCUTANEOUS.....	15
ZONISADE SUSPENSION 100 MG/5ML ORAL....	22